Bispecifics Could Be A Threat To CAR-Ts
But Efficacy May Trump Convenience
Executive Summary
T-cell-engaging bispecific antibodies emerged at ASH as viable competitors for autologous T-cell therapies, but while their off-the-shelf availability is intriguing, it may be too early to say if their safety and efficacy beats CAR-Ts.